
Keywords: adalimumab; biologics; etanercept; infliximab; monitoring; psoriasis; psoriatic arthritis; safety; screening; ustekinumab; AAD; American Academy of Dermatology; ALP; alkaline phosphatase; ALT; alanine transaminase; ANA; antinuclear antibody; AST; aspartat